NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) (TSX: IN) Secures $8M in Underwritten Public Offering
InMed Pharmaceuticals (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), has closed an underwritten public offering. InMed Pharmaceuticals secured approximately US$8 million in gross proceeds, with an aggregate of 1,780,000 common shares, together with accompanying warrants, sold at a public offering price of US$4.50 per share and accompanying warrant. In addition, the underwriters were granted the option to purchase an additional 267,000 common shares and additional warrants to purchase up to an aggregate of 267,000 common shares for a period of 45 days.…







